Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. - Wikidata - awgldk - TriplyDB

Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

http://www.wikidata.org/entity/Q33799732

about

Novel Therapies for Eosinophilic Disorders The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and Fibrosis Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury.Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease.Aerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice.A protective role for IL-13 receptor α 1 in bleomycin-induced pulmonary injury and repair Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?IL-13 is a therapeutic target in radiation lung injury.Facts and promises on lung biomarkers in interstitial lung diseases.A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.Immune Mechanisms in Pulmonary Fibrosis.The path to personalized medicine in asthma.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Interleukin-13 promotes expression of Alix to compromise renal tubular epithelial barrier function.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.New treatment directions for IPF: current status of ongoing and upcoming clinical trials.A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils.Type 2 immunity in tissue repair and fibrosis.Repetitive Intradermal Bleomycin Injections Evokes T Helper Cell 2 Cytokine-driven Pulmonary Fibrosis.A Dataset of 26 Candidate Gene and Pro-Inflammatory Cytokine Variants for Association Studies in Idiopathic Pulmonary Fibrosis: Frequency Distribution in Normal Czech Population.Modulation of pulmonary fibrosis by IL-13Rα2.Drugs and Targets in Fibrosis.Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation.Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice.Epithelial-mesenchymal transition in Crohn's disease.The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis.Novel imaging approaches for small animal models of lung disease (2017 Grover Conference series).Resolution of organ fibrosis.IL-13 induces periostin and eotaxin expression in human primary alveolar epithelial cells: Comparison with paired airway epithelial cells.TRAIL-Dependent Resolution of Pulmonary Fibrosis.Idiopathic Pulmonary Fibrosis (IPF): An Overview CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling

P2860

Q26799600-EB455E9D-998B-40B1-99E5-F1EA3DE576BE Q33904342-671895E5-7FBA-4728-BB34-7ED09C8B8849 Q34534282-B3734BFA-DD93-405E-96CC-D795051D4EA8 Q35086389-69A53BC7-8E63-47EC-957E-12008D667A5E Q35256069-82390B12-0459-44A4-A3FA-145D6B6375DF Q36040475-A6E97F24-29E5-4B16-A17C-16CCCCA3D6AF Q36146139-2D044175-D9C6-448F-89D3-3F7803612F88 Q36438280-0E4218A3-58F1-4538-BA02-AD36F505EFED Q36682162-E55C2BB6-A271-449C-AFF5-691496498CE2 Q37026406-BA8B5420-0DB7-44B4-9AF8-AEEC1F5BE351 Q37080510-D52D8736-C619-4417-A80D-71E144226E07 Q37526117-C1C7ED7A-8A00-4ACE-954B-1EE743F61A19 Q38543042-47E97C84-CBF5-461A-AC25-54371D744319 Q38634828-4F6B8CF4-657C-421B-BBE0-C00F8DA5789E Q38826634-2551B833-8AC8-4AA2-AE43-1A744C5A7553 Q38843261-F5681403-9C2B-4676-A2CD-45C9DFDCA8F3 Q38883893-FA685C35-C0C0-497A-921B-AD27C5C322B8 Q38918934-C713E1B9-6380-4F1B-BF2F-233B22B5B0CD Q38956376-89577FE6-971F-4A7A-9525-AA124AEEF571 Q39330304-4675ED30-60EC-4EC8-98B0-1BE2BD4FC14B Q40067123-8FA01B89-7880-4308-B47A-E9BF7EB82FC5 Q40074887-FB61FB0F-A123-448E-A698-2628F4D398A0 Q40107399-0DF03B9E-764D-40BE-906A-3BBFC4397748 Q42228778-B3F56633-5DF4-4476-B383-DAA6C190D044 Q42830623-2244A355-3136-493C-B6C0-D0FE3AFEC9D5 Q47119118-48D43A90-AE37-48B9-8096-F8D41EDBA587 Q47127150-FCFDA6C0-D5E0-4031-A2C6-F3BAA4A2172B Q47736517-DB13EFAC-B450-4A77-83AA-63230B532DF6 Q47901631-AF444944-83CB-4D9B-83B4-32CE702DC2A9 Q49603082-04C40395-B93C-4D15-AAB1-2FCF1740E642 Q49965391-72BB5386-5649-4D30-9AE1-CCEC99E4E1C8 Q50069018-B80361D6-037C-4F33-9A16-06D22EA386AA Q52685723-8D61D159-70B8-447C-8C26-6359BEE33369 Q52687459-D465E770-DB13-4892-AC7E-7AD07C114CA2 Q54995748-1B0617C3-78AD-48F8-8676-CF4D60A58B28 Q55543508-3F2A610F-845A-4001-AA7E-E6A41C82CFA4 Q57170607-21033534-337D-4361-867D-5FAEA48978DC Q58710919-57557C64-E670-4806-9CD5-6D804769C61A

P2860

Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

http://www.wikidata.org/entity/Q33799732

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeting interleukin-13 with ...... thic pulmonary fibrosis model.

@ast

Targeting interleukin-13 with ...... thic pulmonary fibrosis model.

@en

type

label

Targeting interleukin-13 with ...... thic pulmonary fibrosis model.

@ast

Targeting interleukin-13 with ...... thic pulmonary fibrosis model.

@en

prefLabel

Targeting interleukin-13 with ...... thic pulmonary fibrosis model.

@ast

Targeting interleukin-13 with ...... thic pulmonary fibrosis model.

@en

P1433

Q33799732-A7456D0A-FCC8-44DD-B8E1-3AC74C7D8E08

P1476

Q33799732-A06F6DEF-8D25-4758-974A-7EF27A8D2AFD

P2093

Q33799732-17C13A1E-1839-43E2-BA82-79BB8B69062F

Q33799732-1D2D98CB-86FB-4D8A-ACB2-422F09596A2B

Q33799732-4B79234D-601A-4FC6-94C2-2B374748DCBB

Q33799732-62380F6B-EA60-4024-8C7F-702E03B42940

Q33799732-75F9248D-1C55-4B9E-9CD5-BEBA1372B251

Q33799732-7C600861-2939-4708-80D8-5A412677A53E

Q33799732-91803C33-43A4-4635-BFFB-04732861CABE

Q33799732-9AA053B4-AAC4-4DC3-AA86-8B66822CEECD

Q33799732-A7451202-85F4-4346-BD52-B63C406EEDDB

Q33799732-BF7B7666-321B-4855-8C5E-C3276753658E

P2860

Q33799732-04237AB9-EF82-45AF-833E-075E01B1DB66

Q33799732-107BFDDF-A237-442A-97F5-083C8D927987

Q33799732-136D8958-4F11-448E-AAD6-2F99EB08A33D

Q33799732-1E9356D7-8625-44FE-B996-762F98E8E556

Q33799732-2187E32A-C1E8-4F01-AD1C-3B3F518F8216

Q33799732-218F08DF-F67D-43F9-A219-01AEA7F3CF35

Q33799732-2497B701-30DC-4975-8121-F4B67061A6B3

Q33799732-29700E03-88C9-495B-94BA-6EE67DC51B18

Q33799732-2EF897A8-C1F0-4DA9-B919-615F743AB473

Q33799732-349FF148-B9C5-4C9E-89D7-077165271147

P304

Q33799732-E4A43A53-3117-4544-A852-E9FB089DC07A

P31

Q33799732-4BC163C8-02AE-4A26-AE4F-B5ED3F1F04E2

P356

Q33799732-77DAB002-FCF8-4C4B-9A17-E36E0E689678

P433

Q33799732-EF6C7DD3-7495-43E0-85D6-4C1B955F8EC7

P478

Q33799732-139583C7-EBFA-49A0-B508-F6739B3CDCCE

P50

Q33799732-0DD81A38-30D4-4043-8843-ACF8EBBA4E6E

Q33799732-99E3418B-DACF-4B89-801B-0F019C8979FE

P577

Q33799732-3A9B58B2-0876-4527-AB91-9D21CF7089D7

P5875

Q33799732-BCE4C784-AF6E-4351-9CDC-9049ACCFF28E

P698

Q33799732-B92B2231-24F2-4F34-8D6F-85702CAAE1C5

P921

Q33799732-A5BFA51F-B3EB-4D88-AC65-B7343F92DC2D

Q33799732-b5d255e2-3ee7-4068-a9ae-b7c0b0a2b1fd

P932

Q33799732-25634B3A-16E8-438E-B566-27D2A5728300

P356

RCMB.2013-0342OC

P1433

American Journal of Respiratory Cell and Molecular Biology

P1476

Targeting interleukin-13 with ...... athic pulmonary fibrosis model

@en

P2093

Ana Lucia Coelho

http://www.w3.org/2001/XMLSchema#string

Cory M Hogaboam

http://www.w3.org/2001/XMLSchema#string

Darryl A Knight

http://www.w3.org/2001/XMLSchema#string

Erica L Herzog

http://www.w3.org/2001/XMLSchema#string

Fernando J Martinez

http://www.w3.org/2001/XMLSchema#string

Huilan Zhang

http://www.w3.org/2001/XMLSchema#string

Joyce Lee

http://www.w3.org/2001/XMLSchema#string

Kevin R Flaherty

http://www.w3.org/2001/XMLSchema#string

Matt Bell

http://www.w3.org/2001/XMLSchema#string

Matthew A Sleeman

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

Classification and natural history of the idiopathic interstitial pneumonias

IL-13 effector functions

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

Pulmonary fibrosis: pathogenesis, etiology and regulation

Cutaneous wound healing

The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts.

The clinical course of patients with idiopathic pulmonary fibrosis.

Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis

P304

985-994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1165/RCMB.2013-0342OC

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259269766

http://www.w3.org/2001/XMLSchema#string

P698

24325475

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

4068948

http://www.w3.org/2001/XMLSchema#string